Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
Upon completion of the activity, participants should be able to explain the circumstances – and rationale – under which it is appropriate to initiate or switch a patient with inflammatory bowel disease to a biosimilar.
2. Explain the circumstances under which it is appropriate to initiate or switch a patient with inflammatory bowel disease to a biosimilar
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.